Add to ORKGMinority groups are vastly underrepresented in clinical trial participants and leadership. Because these studies provide innovative and revolutionary treatment options to patients with cancer and have the potential to extend survival, it is imperative that public and private stakeholders, as well as hospital and clinical trial leadership, prioritize equity and inclusion of diverse populations in clinical trial development and recruitment strategies. Achieving equity in clinical trials could be an important step in reducing the overall cancer burden and mortality disparities in vulnerable populations
Recent evidence suggests racial/ethnic minorities, older adults and the economically disadvantaged a...
Disclosures of potential conflicts of interest may be found at the end of this article. An overarchi...
PURPOSE:: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproporti...
Minority groups are vastly underrepresented in clinical trial participants and leadership. Because t...
The United States witnessed a nearly 4‐fold increase in personal health care expenditures between 19...
Racial and ethnic diversity has historically been difficult to achieve in National Cancer Institute-...
Abstract Participation in cancer research trials by minority populations is imperative in reducing d...
Participation in clinical trials is one of the greatest gifts that humanity can give to the fields o...
IntroductionIn recent years, there has been increasing awareness of the lack of diversity among clin...
Background: Study populations in clinical research must reflect US changing demographics, especially...
Background: Racial and ethnic minority groups (REMGs) have low rates of inclusion in cancer trials. ...
Clinical trials are the established research mechanism designed to examine how new medical therapies...
BackgroundStudy populations in clinical research must reflect US changing demographics, especially w...
Research has shown that there continues to be insufficient recruitment of minorities in clinical tri...
Context Despite the importance of diversity of cancer trial participants with regard to race, ethnic...
Recent evidence suggests racial/ethnic minorities, older adults and the economically disadvantaged a...
Disclosures of potential conflicts of interest may be found at the end of this article. An overarchi...
PURPOSE:: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproporti...
Minority groups are vastly underrepresented in clinical trial participants and leadership. Because t...
The United States witnessed a nearly 4‐fold increase in personal health care expenditures between 19...
Racial and ethnic diversity has historically been difficult to achieve in National Cancer Institute-...
Abstract Participation in cancer research trials by minority populations is imperative in reducing d...
Participation in clinical trials is one of the greatest gifts that humanity can give to the fields o...
IntroductionIn recent years, there has been increasing awareness of the lack of diversity among clin...
Background: Study populations in clinical research must reflect US changing demographics, especially...
Background: Racial and ethnic minority groups (REMGs) have low rates of inclusion in cancer trials. ...
Clinical trials are the established research mechanism designed to examine how new medical therapies...
BackgroundStudy populations in clinical research must reflect US changing demographics, especially w...
Research has shown that there continues to be insufficient recruitment of minorities in clinical tri...
Context Despite the importance of diversity of cancer trial participants with regard to race, ethnic...
Recent evidence suggests racial/ethnic minorities, older adults and the economically disadvantaged a...
Disclosures of potential conflicts of interest may be found at the end of this article. An overarchi...
PURPOSE:: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproporti...